NantHealth Inc (NYSE:NH) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday.
Several other equities research analysts also recently commented on NH. Jefferies Group LLC decreased their target price on shares of NantHealth from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. Canaccord Genuity reissued a “buy” rating and set a $6.00 target price (down from $8.00) on shares of NantHealth in a research report on Monday, August 21st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $8.55.
NantHealth (NYSE:NH) opened at 4.63 on Friday. NantHealth has a 1-year low of $4.00 and a 1-year high of $14.62. The firm’s market capitalization is $564.61 million. The stock’s 50 day moving average is $4.46 and its 200-day moving average is $5.81.
NantHealth (NYSE:NH) last posted its earnings results on Thursday, August 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.32). The business had revenue of $26.23 million for the quarter, compared to the consensus estimate of $31.28 million. NantHealth had a negative return on equity of 83.97% and a negative net margin of 267.11%. The company’s revenue was down 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) earnings per share. Analysts forecast that NantHealth will post ($0.70) EPS for the current year.
A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its position in NantHealth by 20.2% in the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after purchasing an additional 71,087 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in NantHealth in the 1st quarter worth about $998,000. Goldman Sachs Group Inc. grew its position in NantHealth by 91.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after purchasing an additional 81,024 shares in the last quarter. Northern Trust Corp grew its position in NantHealth by 133.9% in the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after purchasing an additional 86,955 shares in the last quarter. Finally, State Street Corp grew its position in NantHealth by 88.1% in the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after purchasing an additional 68,963 shares in the last quarter.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.